https://www.statcounter.com/counter/counter.js
Web Analytics
Home » Posts tagged with » Atopic dermatitis
Teva launches Elidel (Pimecrolimus) Cream, 1% generic version in US

Teva launches Elidel (Pimecrolimus) Cream, 1% generic version in US

Teva Pharmaceutical Industries has launched a generic version of Elidel (pimecrolimus) Cream, 1% in the US, a topical prescription medicine indicated for use as a second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate eczema (atopic dermatitis). Elidel (pimecrolimus) Cream, 1% has approval to be used for the treatment of non-immunocompromised […]

LEO Pharma bags licensing rights for atopic dermatitis drug JW1601 from JWP

LEO Pharma, a Danish pharma company, has bagged global exclusive rights for atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP) in a deal worth around KRW450 billion ($402 million). The global licensing agreement will not cover South Korea, the home country of JWP, where the Korean pharma company will keep its exclusive rights over the […]

Continue reading …
Novartis to in-license atopic dermatitis drug MOR106 from MorphoSys, Galapagos

Novartis has agreed to acquire the exclusive global development and marketing rights of atopic dermatitis drug MOR106 from MorphoSys and Galapagos in a deal that could go up to $1.1 billion. The Swiss drugmaker will make an upfront payment of €95 million ($111 million) to Galapagos and MorphoSys apart from potential milestone payments of up […]

Continue reading …
Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]

Continue reading …
Eczema drug Dupixent succeeds in phase 3 atopic dermatitis clinical trial

Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixent (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Update : Dupixent eczema injection gets FDA approval for atopic dermatitis treatment Atopic Dermatitis Clinical Trial […]

Continue reading …